Today's Rundown Featured Story | | | Tuesday, December 4, 2018 Amgen has posted early clinical data on anti-BCMA T cell engager AMG 420 in patients with relapsed or refractory multiple myeloma. The 70% objective response rate and lasting efficacy at the optimum dose show the drug has promise, but time-consuming administration via continuous infusion and the presence of CAR-T competitors cast a shadow over its prospects. |
|
|
Top Stories Tuesday, December 4, 2018 Janssen and Legend Biotech reported updated data from a phase 1/2 study of their BCMA-targeted CAR-T therapy in patients with relapsed or refractory multiple myeloma. In the 57 patients who received the treatment, the overall response rate was 88%, with 74% having a complete response. Tuesday, December 4, 2018 The FDA has published draft guidance on developing NASH drugs that has implications for Gilead and the host of other companies targeting the indication. In the draft, the FDA sets out the endpoints and patient populations it wants companies to look at in phases 2 and 3. Tuesday, December 4, 2018 French-Canadian biotech Domain Therapeutics has another big pharma partner, signing a deal with Germany’s Boehringer Ingelheim to develop new drugs for central nervous system disorders. Monday, December 3, 2018 RedHill Biopharma’s lead asset, antibiotic cocktail RHB-105, bested an amoxicillin combination in patients with H. pylori infection, topline phase 3 data show. The results set RedHill up for an FDA filing in the first half of 2019 and, assuming all goes well, a launch by the end of the year. Tuesday, December 4, 2018 SmartZyme BioPharma is spinning off its protein-based therapeutic platform into a new company—dubbed Carnot BioSciences—as part of a collaboration with Hemoshear Therapeutics aimed at rare metabolic diseases. Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
